Please assess the completion status of the following clinical trial:

Trial Title: Metabolic Manipulation in Chronic Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Optimally-medicated idiopathic dilated cardiomyopathy~* Symptomatic ( NYHA IIb-III)~* Impaired left ventricular systolic function (EF \< 40%)~Exclusion Criteria:~* Abnormal liver function tests (defined as above twice the upper limit of normal (ULN))~* Concomitant use of Amiodarone , Quinidine , Haloperidol or Selective serotonin (5HT) uptake inhibitors such as Fluoxetine and Paroxetine which may inhibit the CYP2D6 enzyme.~* Pre-existing evidence of peripheral neuropathy.~* Women of childbearing potential.~* Patients with implantable cardiac devices (or any other contraindication to MRI).~* Obesity ( BMI \> 32)~* Obstructive sleep apnea syndrome~* Patients with known hypersensitivity to perhexiline~* Patients with impaired renal function (Creatinine \> 250 µmol/L)~* Valvular heart disease defined as more than moderate valvular stenosis or regurgitation.~* Atrial Fibrillation

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Perhexiline (Type: EXPERIMENTAL): perhexiline 100mg bd for 1 month duration
- Placebo (Type: PLACEBO_COMPARATOR): placebo one tablet bd for 1 month duration

Based on this trial design, predict the completion outcome and termination type (if applicable).